EDGE MEDICAL-B (02675) surged more than 9% in late trading, reaching a high of HK$63.75 and setting a new record high since its listing. As of the time of writing, the stock was up 8.87%, trading at HK$63.2, with a turnover of HK$104 million.

Public information indicates that EDGE MEDICAL is a leading surgical robotics company in China's medical device industry, focusing on the design, development, and manufacturing of surgical robots.

According to data from Frost & Sullivan, EDGE MEDICAL is the first company in China and the second globally to have obtained regulatory approval for multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots simultaneously.

Founder Securities believes that EDGE MEDICAL's global IPO attracted a diverse and international group of cornerstone investors to participate in the subscription, reigniting capital market interest in the laparoscopic robotics sector.

China's laparoscopic surgical robot industry currently has a procedure penetration rate of less than 1%, significantly lower than the 21.9% rate in the United States, with over 40% of the market share still dominated by the da Vinci system, indicating substantial room for growth in domestic adoption. With ongoing policy support from the government and accelerated relaxation of equipment licensing, capital market enthusiasm for this sector continues to run high.